Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which medicines and herbal products are damaging livers? egyptian hospital launches Two-Year hunt

NCT ID NCT07830901

NEW Knowledge-focused Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers at Al-Rajhi Liver Hospital in Assiut, Egypt, are studying drug-induced liver injury, a form of liver damage caused by prescription medicines, over-the-counter drugs, herbal products, or dietary supplements. The study has two parts: a review of past medical records from adults already diagnosed with the condition, and a follow-up of adults who develop it during a later period. The team aims to measure how common the injury is, identify the products most often involved, classify the pattern of liver damage, and find which patients are more likely to face serious outcomes such as liver failure, transplant, or death. Participants receive standard medical care from their own doctors; researchers only record routine test results and treatment details.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the study maps which medicines, herbs, and supplements harm the liver most often in this region, doctors could spot drug-induced liver injury earlier and warn patients away from the riskiest products.
What could go wrong
This is an observational study at a single hospital, so its numbers may not reflect other regions or hospitals. It cannot prove that any specific product causes liver damage, only describe patterns among patients who already have it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients (aged 18 years or older) presenting to or admitted to Al-Rajhi Liver Hospital, Assiut University Hospitals, Assiut, Egypt, who fulfill the predefined clinical and biochemical criteria for drug-induced liver injury (DILI) following exposure to a suspected prescription drug, herbal preparation, or dietary supplement.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients aged 18 years or older. * Patients presenting to or admitted to Al-Rajhi Liver Hospital during the study period. * Patients fulfilling the predefined biochemical and clinical criteria for drug-induced liver injury (DILI): * Alanine aminotransferase (ALT) \>= 5 times the upper limit of normal (ULN); or * Alkaline phosphatase (ALP) \>= 2 times the ULN (particularly when accompanied by elevated gamma-glutamyl transferase \[GGT\] and in the absence of a known bone source); or * ALT \>= 3 times the ULN with simultaneous total bilirubin \> 2 times the ULN. * Documented exposure to a suspected medication, herbal preparation, or dietary supplement preceding the onset of liver injury, with a compatible temporal relationship. * For the retrospective cohort: availability of adequate medical records to establish the diagnosis of DILI and assess clinical outcomes. * For the prospective cohort: provision of informed consent for study participation and follow-up (by the patient or a legally authorized representative). Exclusion Criteria: * Patients younger than 18 years * Patients in whom an alternative etiology of acute liver injury is clearly established (e.g., acute viral hepatitis, autoimmune hepatitis, biliary obstruction, ischemic/hypoxic hepatitis) and DILI is considered unlikely * Patients with insufficient clinical or laboratory data to verify whether diagnostic criteria for DILI are fulfilled * Patients in the retrospective cohort with inadequate outcome records where assessment of the primary clinical endpoint is not possible * Patients (or their legal representatives) who decline participation in the prospective cohort

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drug-induced liver injury are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute liver failure drug-induced liver injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Drug-induced liver injury

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.